Dr. Radu I Pacurariu, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 920 Wyoming Ave, Ste # 201, Forty Fort, PA 18704 Phone: 570-288-6115 Fax: 570-288-4941 |
News Archive
A new approach to stimulating immune cells enhances their anticancer activity, resulting in a powerful anti-tumor response in mice, according to a study by researchers at the National Cancer Institute, a part of the National Institutes of Health. This work represents an important advance in the development of immunotherapy for cancer and appears online June 14, 2009 in Nature Medicine.
GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), was pleased to hear the announcement today of partial success in the recently completed Phase 3 trial in Thailand of a candidate HIV/AIDS vaccine owned by Sanofi-Aventis and Global Solutions for Infectious Diseases.
AGTC, a privately held company, and Icagen, Inc. today announced the completion of an agreement for the purchase and sale of certain patent rights between the companies. Icagen is transferring its rights to patents relating to the ion channel gene CNGB3, which has been linked to certain disorders of the eye. Under the terms of the agreement, Icagen has assigned ownership of the patents to AGTC, which intends to use the patented technology for gene therapy as a potential treatment for Achromatopsia, a severe form of daytime blindness.
Scientists have succeeded in reducing levels of the bovine leukemia virus in cows with severe infections by combining an immune checkpoint inhibitor and an enzyme inhibitor.
Scientists at the Albert Einstein College of Medicine have discovered a novel strategy by which the bacterium that causes tuberculosis may soon be able to resist the effects of antibiotics known as fluoroquinolones.
› Verified 2 days ago